BioSpace News Archive

Gilead Sciences, Inc. and Jounce Therapeutics, Inc. amended their existing license agreement for GS-1811, enabling Gilead to buy out remaining contingent payments potentially due under the license agreement executed in August 2020.

Ampio Pharmaceuticals, Inc. announced that it has received notification from The NYSE American LLC stating that the Company has regained compliance with the NYSE American’s continued listing standards.

InnoCare Pharma announced the approval of tafasitamab in combination with lenalidomide for adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant by the Department of Health, the Hong Kong Special Administrative Region, China.

EOFlow Co., Ltd., a provider of wearable drug delivery systems, announced that it submitted a 510 application to the U.S. FDA for its wearable disposable insulin pump EOPatch on December 27.

SpringWorks Therapeutics, Inc. announced that the Company has completed the submission of a New Drug Application to the United States Food and Drug Administration for nirogacestat, an investigational gamma secretase inhibitor, for the treatment of adults with desmoid tumors.

TRACON Pharmaceuticals, a clinical stage biopharmaceutical company utilizing a cost-efficient, CRO-independent product development platform to advance its pipeline of novel targeted cancer therapeutics and to partner with other life science companies, announced entry into an up to $30 million non-recourse financing agreement.

CG Oncology, Inc. announced that Arthur Kuan, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 11, 2023 at 4pm Pacific Standard Time.

PolarityTE, Inc. announced that it signed a non-binding letter of intent with Michael Brauser for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash.

Deka Biosciences, Inc., a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, announced the submission of an Investigational New Drug application to the U.S. Food and Drug Administration on December 23, 2022.

Adaptive Biotechnologies Corporation announced it will be participating in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, CA.